PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Esketamine→

Esketamine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
33643-46-8
Molecular formula
C13H16ClNO
Molecular weight
237.72 g/mol
Drug class
S-enantiomer of ketaminenon-selective, non-competitive NMDA receptor antagonist
Mechanism of action
Non-competitively antagonises NMDA glutamate receptors. Its antidepressant effects may involve downstream changes in synaptic plasticity and glutamatergic signalling; the precise mechanism underlying clinical response is not fully established.
Indications / reported uses
  • Treatment-resistant depression in adults, in conjunction with an oral antidepressant under the US product indication
  • Depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour, in conjunction with standard care; the label does not establish prevention of suicide or reduction of suicidal behaviour

Sources: US DailyMed — SPRAVATO (esketamine) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Esketamine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Esketamine Permitted Daily Exposure (PDE) report (the Esketamine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Esketamine Occupational Exposure Limit (OEL) report (the Esketamine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.